Prevalence and clinical characteristics of insulin-treated, anti-GAD-positive, type 2 diabetic subjects in an outpatient clinical department of a Dutch teaching hospital

Netherlands Journal of Medicine

Volumn 64, Issue 4, 2006, Pages 114-118

  Romkens T E H ^a   Kusters, G C M ^a   Netea, M G ^b   Netten, P M ^a  

^a JEROEN BOSCH HOSPITAL   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Anti GAD; Autoimmunity; LADA; Type 2 diabetes

Indexed keywords

GLUTAMATE DECARBOXYLASE ANTIBODY; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; ORAL ANTIDIABETIC AGENT;

ADULT; AGED; ANTIBODY DETECTION; ANTIBODY TITER; ARTICLE; AUTOIMMUNITY; BODY MASS; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; CLINICAL FEATURE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETIC ANGIOPATHY; DIABETIC HYPERTENSION; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; FEMALE; HUMAN; HYPOTHYROIDISM; INSULIN TREATMENT; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MICROALBUMINURIA; NETHERLANDS; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTPATIENT CARE; PERIPHERAL VASCULAR DISEASE; TEACHING HOSPITAL;

AUTOANTIBODIES; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; FEMALE; GLUTAMATE DECARBOXYLASE; HOSPITALS, TEACHING; HUMANS; INSULIN; MALE; METABOLIC SYNDROME X; MIDDLE AGED; NETHERLANDS; OUTPATIENT CLINICS, HOSPITAL; PREVALENCE;

EID: 33645944029     PISSN: 03002977     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. National diabetes data group. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 1979;28:1039-57.
2. Report the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 2003;26:S5-S20.
3. Alberti KG, Zimmet PZ, for the WHO Consultation. Definition, diagnosis and classification of diabetes mellitus and its complications. I. Diagnosis and classification of diabetes mellitus: provisional report of a WHO Consultation. Diabet Med 1998;15:539-53.
4. Verge CF, Giani R, Kawasaki E, et al. Prediction of type 1 diabetes in first degree relatives using a combination of insulin, GAD, and ICA512bdc/IA2-autoantibodies. Diabetes 1996;45:926-33.
5. Seissler J, de Sonnaville J, Morgenthaler N, et al. Immunological heterogeneity in type 1 diabetes: pressence of distinct autoantibody patterns in patients with acute onset and slowly progressive disease. Diabetologia 1998;41:891-7.
6. Tuomi T, Groop LC, Zimmet PZ, Rowley MJ, Knowles W, Mackay IR. Antibodies to glutamic acid decarboxylase reveal latent autimmune diabetes mellitus in adults with a non-insulin-dependent onset of disease. Diabetes 1993;42:359-62.
7. No authors listed. Insulin-dependent? Lancet 1985;2:809-10.
8. Groop LC, Bottazzo GF, Doniach D. Islet cell antibodies identify latent type 1 diabetes in patients aged 35-75 years at diagnosis. Diabetes 1986;35:237-41.
9. Palmer JP, Hirsch IB. What's in a name; Latent autoimmune diabetes of the adult, type 1.5, adult onset, and type 1. Diabetes Care 2003;2:536-7.
10. Gale EAM. Latent autoimmune diabetes in adults: a guide for the perplexed. Diabetologia 2005;48:2195-9.
11. Tuomi T, Carlsson A, Li H, et al. Clinical and genetic characteristics of type 2 diabetes with and without GAD antibodies. Diabetes 1999;48:150-7.
12. Zimmet P, Turner R, Mc Carty D, Rowley M, Mackay I. Crucial points at diagnosis: type 2 diabetes or slow type 1 diabetes. Diabetes Care 1999;22:59-64.
13. Fourlanos S, Dotta F, Greenbaum C, et al. Latent autoimmune diabetes in adults (LADA) should be less latent. Diabetologia 2005;48:2206-12.
14. Bosi EP, Garancini NT, Poggiali F, Bonifacio E, Gallus G. Low prevalence of islet autoimmunity in adult diabetes and low predictive value of islet autoantibodies in the general adult population of northern Italy. Diabetologia 1999;42:840-4.
15. Bruno G, De Salvia A, Arcari R, et al. Clinical, immunological, and genetic heterogenity of diabetes in an Italian population-based cohort of lean newly diagnosed patients aged 30-54 years. Diabetes Care 1999;22:50-5.
16. Turner R, Stratton I, Horton V, et al. UKPDS 25: autoantibodies to islet cytoplasm and glutamic acid decarboxylase for prediction of insulin requirements in type 2. Lancet 1997;350:1288-93.
17. Gambelunghe G, Forini F, Laureti S, et al. Increased risk for enocrine autoimmunity in Italian type 2 diabetic patients with GAD65 autoantibodies. Clin Endocrinol 2000;52(5):563-73.
18. Lorini R, d'Annuncio G, Vitali L, et al. IDDM and autoimmune thyroid disease in the pediatric age group. J Pediat Endo Met 1996;9:89-94.
19. Hansen D, Bennedbaek FN, Hansen LK, Hoier-Madsen M, Jacobsen BB, Hegedus L. Thyroidfunction, morphology and autoimmunity in young patients with insulin dependent diabetes mellitus. Eur J Endocrinol 1999;140:512-8.
20. Falorni A. Immunologic and genetic aspects of latent autoimmune diabetes in the adult. Minerva Endocrinol 2003;28(4):297-312.
21. Irvine WJ, Mc Callum CJ, Gray RS, et al. Pancreatic islet-cell antibodies in diabetes mellitus correlated with the duration and type of diabetes, coexistent autoimmune disease, and HLA-type. Diabetes 1977;26:138-47.
22. Grasso YZ, Reddy SSK, Rosenfeld CR, et al. Autoantibodies to IA-2 and GAD65 in patients with type 2 diabetes mellitus of varied duration: prevalence and correlation with clinical features. Endocrine Practice 2001;7(5):339-45.
23. Isomaa B, Almgren P, Henricsson M, et al. Chronic complications in patients with slowly progressing autoimmune type 1 diabetes (LADA). Diabetes Care 1999;22:1347-53.
24. Hosszufalusi N, Vatay A, Rajczy K, et al. Similar genetic features and different islet cell autoantibody pattern of latent autoimmune diabetes in adults (LADA) compared with adult-onset type 1 diabetes with rapid progression. Diabetes Care 2003;26:452-7.
25. Li H, Lindholm E, Almgren P, et al. Possible human leukocyte antigen-mediated genetic interaction between type 1 and type 2 diabetes. J Clin Endocrinol Metab 2001;86(2):574-82.
26. Lethagan A, Groop L, Lindholm E, et al. Metabolic comparison of rapid and slow onset autoimmune diabetes in newly-diagnosed patients older than 35 years at onset. Diabetologia 2002;45(suppl 2):A155.
27. Pozzilli P, Di Mario U. Autoimmune diabetes not requiring insulin at diagnosis (Latent Autoimmune Diabetes of the Adult). Diabetes Care 2001;24:1460-7.
28. Kobayashi T, Nakanishi K, Murase T, Kosaka K. Small doses of subcutaneous insulin as a strategy for preventing slowly progressive B-cell failure in islet cell antibody positive with clinical features of NIDDM. Diabetes 1996;44:622-6.
29. Cabrera-Rode E, Perich P, Diaz-Horta O, et al. Slowly progressing type 1 diabetes: persistence of islet cell autoantibodies is related to glibenclamide treatment. Autoimmunity 2002;35:469-74.
30. Davis TME, Wright AD, Mehta ZM, et al. Islet autoantibodies in clinically diagnosed type 2 diabetes: prevalence and relationship with metabolic control (UKPDS 70). Diabetologia 2005;48:695-702.
31. Beales PE, Rosignoli G, Liddi R, Barchelor K, Pozzili P. The prevention of diabetes using rosiglitazone in the non-obese diabetic mouse. Diabetes Res Clin Pract 2000;50(suppl1):1518.